Diffuse large B cell lymphoma laboratory tests: Difference between revisions

	Diffuse large B cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Diagnosis
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Biopsy
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Diffuse large B cell lymphoma laboratory tests On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Diffuse large B cell lymphoma laboratory tests All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Diffuse large B cell lymphoma laboratory tests
CDC on Diffuse large B cell lymphoma laboratory tests
Diffuse large B cell lymphoma laboratory tests in the news
Blogs on Diffuse large B cell lymphoma laboratory tests
Directions to Hospitals Treating Diffuse large B cell lymphoma
Risk calculators and risk factors for Diffuse large B cell lymphoma laboratory tests

Revision as of 15:43, 22 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

laboratory studies including

Complete Blood Picture
Serum lactate dehydrogenase (LDH)
Comprehensive metabolic panel
CT chest/abdominal/pelvic with oral and intravenous contrast (unless co-existent renal insufficiency)
MUGA scan or echocardiograms are recommended when anthracyclines and anthracenedione containing regimens are used
Bone marrow biopsy with or without aspirate is essential in all cases where treatment is considered; however, there are circumstances where it may be deferred
Hepatitis B testing prior to initiation of treatment in all patients who will receive anti CD20 monoclonal antibody-based regimens and anyone with a risk factor
Hepatitis C testing is needed in high-risk patients

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Diffuse large B cell lymphoma}}
+{{CMG}}
-Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
+==Overview==
+==Laboratory Tests==
+laboratory studies including
+* Complete Blood Picture
+* Serum lactate dehydrogenase (LDH)
+* Comprehensive metabolic panel
+* CT chest/abdominal/pelvic with oral and intravenous contrast (unless co-existent renal insufficiency)
+* MUGA scan or echocardiograms are recommended when anthracyclines and anthracenedione containing regimens are used
+* Bone marrow biopsy with or without aspirate is essential in all cases where treatment is considered; however, there are circumstances where it may be deferred
+* Hepatitis B testing prior to initiation of treatment in all patients who will receive anti CD20 monoclonal antibody-based regimens and anyone with a risk factor
+* Hepatitis C testing is needed in high-risk patients
 ==References==
 {{reflist|2}}
-[[Category:Needs content]]
 [[Category:Disease]]
 [[Category:Types of cancer]]